Worldwide tracked shipping | Est. 9–14 business days

Your cart

Your cart is empty.

Start browsing

Free shipping on orders over €500.

Subtotal€0
Proceed to checkout
Analytical laboratory bench for the article GHK-cu vs KLOW: which to pick for a research project
Research notes

GHK-cu vs KLOW: which to pick for a research project

A buyer's comparison of GHK-Cu and KLOW for laboratory research: composition, published evidence, certificate fields and a decision sequence for choosing between a single copper peptide and a four-component blend.

The question ghk cu vs klow has a short answer: they are not two versions of the same material.

Both are supplied for laboratory research, and both have a published certificate from a named laboratory outside AKH on their product pages: GHK-Cu 100mg and KLOW 80mg. This comparison sets out what each vial contains, how the published evidence differs, what the two batch reports document, and the sequence a researcher can use to choose between a single compound and a fixed blend.

Key takeaways

  • The GHK-Cu evidence record lists 15 published studies; the KLOW record lists 16, all component-level, with no study of the four-peptide blend in any model.
  • Controlled human evidence for GHK-Cu is thin and mixed; the two largest randomised trials of topical copper tripeptide were negative on their objective endpoints.
  • Each product has its own batch certificate: GHK-Cu batch 26155 and KLOW batch 26145, both tested by the Brown Institute of Biomolecular Research.
  • The choice turns on whether a design needs one variable or a fixed four-component mixture, not on vial size.
01

What GHK-Cu and KLOW each contain

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine. The research record gives the formula C14H24CuN6O4, a molecular weight of 403.92 g/mol and PubChem CID 378611. The product is supplied as 100mg of lyophilised (freeze-dried) powder, and the listing states a purity of 99.64%.

KLOW is a single lyophilised vial containing four peptides: GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg, for a stated total of 80mg, with a listing purity of 99.82%. The KLOW page describes GHK-Cu as the blend's largest component by mass. The four components are supplied together in a fixed ratio, so a sample taken from the vial is exposed to all four peptides at once.

FieldGHK-CuKLOW
Stated form100mg lyophilised powder80mg lyophilised blend
CompositionGHK-Cu onlyGHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, KPV 10mg
Batch on the published certificate2615526145
Test date03 Aug 202624 Jul 2026
LaboratoryBrown Institute of Biomolecular ResearchBrown Institute of Biomolecular Research
Stated purity99.64%99.82%
02

How the published research differs

The GHK-Cu research record lists 15 published studies, 6 of them human, with 10 published since 2023. In fibroblast cultures, the record reports increased collagen and glycosaminoglycan synthesis at picomolar to nanomolar concentrations. A 2026 PRISMA systematic review located only 20 studies of GHK-Cu as a standalone aesthetic intervention, 18 preclinical and 2 randomised controlled trials. The record notes that the two largest randomised trials of topical copper tripeptide were negative on their objective endpoints, and a 2025 review concluded that published information on skin permeability for GHK-Cu and Pal-GHK is insufficient.

The KLOW record lists 16 published studies, 10 since 2023, and states that a systematic search of PubMed and Europe PMC returned no published study of the four-peptide blend in any model. Only one published study examines any two components together: a 2026 experiment in 32 male Sprague-Dawley rats with Achilles tendon transection and repair, which compared BPC-157, TB-500 and a combination arm over four weeks and reported that the combination did not confer additional benefit over either peptide given alone. The component evidence varies widely: BPC-157 rests almost entirely on rodent work with two very small uncontrolled human pilots, thymosin beta-4 has two randomised phase 2 wound trials, and KPV has in vitro and animal work with no published human dermatology trial.

The 2026 orthopaedic review groups GHK-Cu with BPC-157 and TB-500 among wound-healing peptides and states that preclinical studies are promising while clinical trials are currently lacking. The design consequence is attribution: a sample exposed to GHK-Cu alone can be read against the GHK-Cu literature, while a sample exposed to the KLOW vial is exposed to four sequences at once.

03

Reading the two certificates side by side

Both products have one published certificate on their product page, and each is a report from a named laboratory outside AKH, ordered by the manufacturer. The archive describes each row as one certificate, one batch, tested once. GHK-Cu is covered by batch 26155, tested 03 Aug 2026 by the Brown Institute of Biomolecular Research, with a stated purity of 99.64%.

KLOW is covered by batch 26145, tested 24 Jul 2026 by the same laboratory, with a stated purity of 99.82%, task reference #1812441 and a results line listing Klow(TB+BPC-157+GHK+KPV) at 80mg total, with component masses of 10mg, 10mg, 50mg, and 10mg, and purity 99.82%. Both figures are chromatographic purity results for their batch. The GHK-Cu research record notes that a chromatographic purity result does not resolve the difference between powder mass and peptide mass, because lyophilised peptide is normally supplied as an acetate or trifluoroacetate salt and carries residual water. The KLOW results line gives four component masses but one purity figure for the blend. The batch number is the field that ties each report to a container.

04

How to choose between them for a research project

The decision is a research-design question rather than a product-ranking question. Four checks settle it.

  1. 01

    Name the variable

    If the question concerns one copper tripeptide, a single-compound vial keeps the variable singular. KLOW supplies four peptides together in a fixed ratio, so GHK-Cu cannot be varied independently within that vial.

  2. 02

    Check the evidence tier

    GHK-Cu has a standalone record with mixed controlled human data. KLOW has component-level records only, and the research record states that no study of the blend exists in any model.

  3. 03

    Match the batch to the container

    Read the batch number, test date and laboratory on the product page, then compare the same row in the COA archive before ordering.

  4. 04

    Keep identity and quantity separate

    The stated fill, the component masses and the purity figure describe different things. Neither published report resolves powder mass into peptide mass.

05

Where to buy each and what to check before ordering

The GHK-Cu page lists the 100mg single-compound vial with batch 26155 and links its certificate; the KLOW page lists the 80mg four-component vial with batch 26145 and its report. The two buying routes are GHK-Cu 100mg and KLOW 80mg.

The checks are the same for either: confirm the batch number against the archive, read the results line, confirm the stated fill and composition, and check the delivery window. AKH states worldwide delivery in a 9 to 14 day window.

Both listings are supplied for laboratory research only and state that they are not for human or veterinary use. A certificate documents measurements for a batch; it is not a regulatory approval and does not change that intended-use statement.

Common questions.

Is KLOW just GHK-Cu with extra peptides added?

The KLOW page lists GHK-Cu at 50mg within an 80mg total, alongside BPC-157 10mg, TB-500 10mg and KPV 10mg, and describes GHK-Cu as the blend's largest component by mass. The four are supplied together in a fixed ratio, so the vial is not a GHK-Cu product with a trace addition.

How does a researcher read the GHK-Cu certificate against the KLOW certificate?

Start with the batch, date and laboratory. GHK-Cu batch 26155 was tested 03 Aug 2026 and KLOW batch 26145 on 24 Jul 2026, both by the Brown Institute of Biomolecular Research. The GHK-Cu results line covers one compound and one fill; the KLOW line covers four component masses and one blend purity figure.

Does the GHK-Cu certificate cover the GHK-Cu inside a KLOW vial?

No. The certificate for batch 26155 covers the 100mg GHK-Cu product. The KLOW vial is covered by its own report for batch 26145, which lists the blend's four component masses and a single purity figure. A report for one product does not document a different product's batch.

Why is GHK-Cu the largest component in the KLOW blend?

The KLOW page lists GHK-Cu at 50mg of the stated 80mg total and describes it as the blend's largest component by mass, with the other three at 10mg each. The ratio is a product specification; the research record states that no published study of the four-peptide blend exists in any model.

For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice.